What is William Blair's Forecast for Xencor Q2 Earnings?

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Analysts at William Blair reduced their Q2 2025 earnings estimates for Xencor in a research note issued to investors on Wednesday, May 7th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of ($0.87) per share for the quarter, down from their previous estimate of ($0.82). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. William Blair also issued estimates for Xencor's Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($3.33) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.32) EPS, FY2027 earnings at ($3.15) EPS and FY2028 earnings at ($3.24) EPS.

Several other analysts have also recently commented on the company. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wedbush restated an "outperform" rating and set a $31.00 price target on shares of Xencor in a research report on Wednesday, April 30th. Barclays dropped their price objective on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday, May 8th. Finally, Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.50.

Xencor Price Performance

Shares of NASDAQ:XNCR traded down $0.10 during trading on Monday, reaching $8.10. 82,184 shares of the company's stock traded hands, compared to its average volume of 646,337. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor has a fifty-two week low of $7.16 and a fifty-two week high of $27.24. The company has a 50-day simple moving average of $10.29 and a 200-day simple moving average of $17.30. The firm has a market cap of $576.33 million, a PE ratio of -2.53 and a beta of 0.99.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. During the same period in the prior year, the business posted ($1.11) EPS. The company's quarterly revenue was up 104.6% on a year-over-year basis.

Insider Buying and Selling

In related news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the transaction, the executive vice president now owns 49,169 shares of the company's stock, valued at approximately $542,334.07. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.76% of the stock is owned by insiders.

Hedge Funds Weigh In On Xencor

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC boosted its stake in Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Xencor during the 4th quarter worth about $34,000. State of Wyoming bought a new position in Xencor during the 1st quarter valued at about $34,000. CWM LLC grew its stake in Xencor by 195.5% during the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 2,231 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 508 shares in the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.